Bernstein Maintains Outperform on Medline, Lowers Price Target to $54
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Bernstein analyst Lee Hambright maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $56 to $54.
Bernstein analyst Lee Hambright maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $56 to $54.